Screener
BridgeBio Pharma BBIO Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: BridgeBio Pharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001743881-26-000019
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Treasury stock, at cost; 8,678,997 shares as of March 31, 2026; 7,597,172 shares as of December 31, 2025 | (405,776) | (323,276) |
| Additional paid-in capital | 2,112,454 | 2,057,646 |
| Accumulated other comprehensive income (loss) | (8) | 12 |
| Accumulated deficit | (3,985,237) | (3,821,194) |
| Total BridgeBio stockholders’ deficit | (2,278,363) | (2,086,610) |
| Noncontrolling interests | 10,439 | 10,599 |
| Total stockholders’ deficit | (2,267,924) | (2,076,011) |
| Total liabilities, redeemable convertible noncontrolling interests and stockholders’ deficit | $1,370,981 | $936,025 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's total equity?
- BridgeBio Pharma (BBIO) reported total equity of -$2.28B in Q1 2026.
- How has BridgeBio Pharma's total equity changed year-over-year?
- BridgeBio Pharma's total equity decreased by 38.2% year-over-year, from -$1.65B to -$2.28B.
- What is the long-term trend for BridgeBio Pharma's total equity?
- Over 5 years (2020 to 2025), BridgeBio Pharma's total equity has grown at a 104.8% compound annual growth rate (CAGR), from $57.91M to -$2.09B.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about BridgeBio Pharma's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude